![Stacie Lindsey: Compass Therapeutics completed enrollment of COMPANION-002](https://oncodaily.com/pub/uploads/2024/08/stacie-e1723043735647.png)
Photo taken from
Stacie Lindsey/X
Aug 7, 2024, 11:52
Stacie Lindsey: Compass Therapeutics completed enrollment of COMPANION-002
Stacie Lindsey, CEO at Cholangiocarcinoma Foundation, shared a post on LinkedIn:
“We are happy that our Industry Partner Compass Therapeutics completed enrollment of COMPANION-002, a Phase 2/3 clinical trial for patients with biliary tract cancers. This milestone for our partner is also a milestone for the CCF community. Thank you to all the patients who participated.”
Quoting Cholangiocarcinoma Foundation‘s post:
“Today, Compass Therapeutics completed enrollment of COMPANION-002, a Phase 2/3 clinical trial. A clinical research milestone for our partner is also a milestone for the CCF. A Thank You Message to patients who participated.”
Source: Stacie Lindsey/X and Cholangiocarcinoma Foundation/X
Aug 11, 2024, 06:38
Aug 11, 2024, 05:36
Aug 11, 2024, 05:12
Aug 11, 2024, 04:55